Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial

Autor: Bhatt, DL, Steg, PG, Brinton, EA, Jacobson, TA, Miller, M, Tardif, J-C, Ketchum, SB, Doyle, RT, Murphy, SA, Soni, PN, Braeckman, RA, Juliano, RA, Ballantyne, CM

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid-targeted therapies beyond low-density lipoprotein cholesterol (LDL-C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::ab63b34b14be795aca42f35e9e1b245c
http://hdl.handle.net/10044/1/49980

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

Autor: Szarek M; Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; CPC Clinical Research, Aurora, Colorado, USA; State University of New York, Downstate Health Sciences University, Brooklyn, New York, USA. Electronic address: michael.szarek@cpcmed.org., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Miller M; Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA., Brinton EA; Utah Lipid Center, Salt Lake City, Utah, USA., Jacobson TA; Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada., Ballantyne CM; Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, Texas, USA., Mason RP; Elucida Research, Boston, Massachusetts, USA., Ketchum SB; Amarin Pharma, Inc, Bridgewater, New Jersey, USA., Lira Pineda A; Amarin Pharma, Inc, Bridgewater, New Jersey, USA., Doyle RT Jr; Amarin Pharma, Inc, Bridgewater, New Jersey, USA., Steg PG; Université Paris-Cité, INSERM-UMR1148, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, and Institut Universitaire de France, Paris, France.

Publikováno v: Journal of the American College of Cardiology [J Am Coll Cardiol] 2024 Apr 23; Vol. 83 (16), pp. 1529-1539. Date of Electronic Publication: 2024 Mar 25.

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.

Autor: Miller M; Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center and Hospital of the University of Pennsylvania, 3900 Woodland Avenue, Philadelphia, PA 19104-4551, USA., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, NewYork, NY, USA., Brinton EA; Utah Lipid Center, Salt Lake City, UT, USA., Jacobson TA; Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Steg PG; Université de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris, France., Pineda AL; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Ketchum SB; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Doyle RT Jr; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal, Canada., Ballantyne CM; Department of Medicine, Baylor College of Medicine, Texas Heart Institute, Houston, TX, USA.

Publikováno v: European heart journal open [Eur Heart J Open] 2023 Nov 12; Vol. 3 (6), pp. oead114. Date of Electronic Publication: 2023 Nov 12 (Print Publication: 2023).

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.

Autor: Gaba P; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Bhatt DL; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: DLBhattMD@post.Harvard.edu., Steg PG; Université de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris, France., Miller M; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA., Brinton EA; Utah Lipid Center, Salt Lake City, Utah, USA., Jacobson TA; Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Ketchum SB; Amarin Pharma, Inc (Amarin), Bridgewater, New Jersey, USA., Juliano RA; Amarin Pharma, Inc (Amarin), Bridgewater, New Jersey, USA., Jiao L; Amarin Pharma, Inc (Amarin), Bridgewater, New Jersey, USA., Doyle RT Jr; Amarin Pharma, Inc (Amarin), Bridgewater, New Jersey, USA., Granowitz C; Amarin Pharma, Inc (Amarin), Bridgewater, New Jersey, USA., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada., Giugliano RP; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Martens FMAC; Werkgroep Cardiologische centra Nederland (WCN: Dutch Network for Cardiovascular Research) and the Department of Cardiology, Deventer Hospital, Deventer, the Netherlands., Gibson CM; Department of Cardiovascular Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Ballantyne CM; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.

Publikováno v: Journal of the American College of Cardiology [J Am Coll Cardiol] 2022 May 03; Vol. 79 (17), pp. 1660-1671.

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.

Autor: Verma S; Montreal Heart Institute, Université de Montréal, Quebec, Canada (J-C.T.)., Bhatt DL; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B., R.P.G.)., Steg PG; Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, and Institut National de la Santé et de la Recherche Médicale U-1148, Paris, France (P.G.S.)., Miller M; Department of Medicine, University of Maryland School of Medicine, Baltimore (M.M.)., Brinton EA; Utah Lipid Center, Salt Lake City (E.A.B.)., Jacobson TA; Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, GA (T.A.J.)., Dhingra NK; Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, ON, Canada (S.V., N.K.D.)., Ketchum SB; Amarin Pharma Inc, Bridgewater, NJ (S.B.K., R.A.J., L.J., R.T.D., C.G.)., Juliano RA; Amarin Pharma Inc, Bridgewater, NJ (S.B.K., R.A.J., L.J., R.T.D., C.G.)., Jiao L; Amarin Pharma Inc, Bridgewater, NJ (S.B.K., R.A.J., L.J., R.T.D., C.G.)., Doyle RT Jr; Amarin Pharma Inc, Bridgewater, NJ (S.B.K., R.A.J., L.J., R.T.D., C.G.)., Granowitz C; Amarin Pharma Inc, Bridgewater, NJ (S.B.K., R.A.J., L.J., R.T.D., C.G.)., Gibson CM; Baim Clinical Research Institute, Boston, MA (C.M.G., D.P.)., Pinto D; Baim Clinical Research Institute, Boston, MA (C.M.G., D.P.)., Giugliano RP; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B., R.P.G.)., Budoff MJ; David Geffen School of Medicine, Lundquist Institute, Torrance, CA (M.J.B.)., Mason RP; Elucida Research, Beverly, MA (R.P.M.)., Tardif JC; Montreal Heart Institute, Université de Montréal, Quebec, Canada (J-C.T.)., Ballantyne CM; Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (C.M.B.).

Publikováno v: Circulation [Circulation] 2021 Dec 07; Vol. 144 (23), pp. 1845-1855. Date of Electronic Publication: 2021 Oct 28.